Ambit

Ambit Biosciences is a biopharmaceutical company founded in 2000 with a focus on discovering and developing small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other conditions. The company's lead compound, AC220, is a highly selective FMS-like tyrosine kinase-3 (FLT3) inhibitor currently in clinical trials for patients with relapsed or refractory AML. Ambit is collaborating with Astellas Pharma Inc. to co-develop and commercialize FLT3 kinase inhibitors for both oncology and non-oncology purposes. Aside from AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Moreover, their preclinical pipeline features CEP-32496, a BRAF inhibitor licensed to Cephalon. The company received a $50.00M venture round investment on 06 November 2012 from a group of prominent investors including Forward Ventures, OrbiMed, Aisling Capital, GIMV, GrowthWorks Capital, Radius Ventures, Apposite Capital, Roche Venture Fund, and MedImmune Ventures. Ambit Biosciences aims to drive breakthroughs in cancer and inflammatory disease treatment through pioneering kinase inhibitor research and innovative clinical collaborations within the biopharma, biotechnology, and health care industries.